Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS

Trial Details

NCT ID
NCT06817161
Phase
PHASE3
Sponsor
Centre Francois Baclesse
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • transcutaneous auricular vagus nerve stimulation
  • Placebo device
Locations (sample)
  • Caen, France|49.18585,-0.35912
  • Caen, France|49.18585,-0.35912
  • Lille, France|50.63391,3.05512
  • Rouen, France|49.44313,1.09932

Key Eligibility Criteria

  • Patient ≥ 18 years old
  • Histologically proven epithelial ovarian carcinoma
  • FIGO stage ≥ IIB
  • Patient candidate for first line chemotherapy treatment (alone, neoadjuvant or adjuvant)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →